Jingqin Wu received her PhD degree from the Department of Medicine at the University of Sydney. As a research fellow at the University of Sydney and the University of Newcastle, she has focused on using state-of-the-art multi-omics technologies to answer biomedical questions. She has worked on a wide range of data-driven research projects, including using next-generation-sequencing (NGS) and genome-wide association studies (GWAS) to study schizophrenia, investigating HIV-host interactions in relation to disease progression and therapy effects, comparative genomics of fungal pathogens, and multidrug resistance in Staphylococci. 

In 2021, Jingqin joined the Metabolomics laboratory at the Baker Institute. Her current work focuses on using machine learning methods to develop polygenic and lipidomic risk scores to improve cardiovascular disease (CVD) prediction and risk stratification. By addressing key challenges in CVD risk assessment, she is dedicated to translating research findings into clinical applications.